Articles by Jill Wechsler - Pharmaceutical Executive

ADVERTISEMENT

Articles by Jill Wechsler

Clinical Trial Sponsors Struggle with Data Disclosure Requirements

Policies to widen access to patient level data from clinical trials are gaining traction, despite strong opposition from research sponsors that such initiatives will undermine patient privacy and incentives for new drug development.
Nov 25, 2013

Research sponsors argue that widening access to patient level data from clinical trials will undermine patient privacy and incentives for new drug development.

Transparency Troubles for Pharma

Nov 1, 2013

High prices, murky financial relations, and a reluctance to disclose clinical data undermine public trust in industry and the research enterprise.

The Brand–Generic Wars Heat Up

Oct 10, 2013

As insurers, payers, and drug plan operators eye increased generic drug use as key to cutting healthcare costs, pharma companies are ramping up efforts to delay marketing of copycat products.

Brand-Generic Wars Heat Up

Oct 1, 2013

Tension mounts over biosimilars, co-pay coupons, trade, and testing.

Biopharma Innovation in Trouble?

Sep 1, 2013

Rising costs will mean a drop in anticipated NDAs next year, reflecting an ever-longer and more costly drug-development process that is squeezing pharma investment in R&D.

Costs and Coverage Challenge Medicare Drug Plans

Aug 1, 2013

Rate cuts and fraud concerns create problems for Part D plans and Part B providers.

Seeking Supply Chain Security

Jul 1, 2013

FDA wants pharma leaders to do more to ensure drug quality at home and abroad. Our Washington correspondent Jill Wechsler reports.

Washington Report: Innovation, Coverage, and Costs

Jun 1, 2013

The backlash against high prices for new medicines will impact research, patent exclusivity, and drug benefits.

Manufacturers Under Pressure to Manage Painkillers

Opioid abuse generates calls for efforts to curb distribution, develop abuse-resistant formulations.
May 6, 2013

Opioid abuse generates calls for efforts to curb distribution, develop abuse-resistant formulations.

ADVERTISEMENT

Click here